Molecular Partners to Present at Upcoming Healthcare Investor Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET.

The webcasted presentation will be made available on the Molecular Partners website.

About Molecular Partners AGMolecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs

For further details, please contact: 
Seth Lewis 
[email protected] 
Tel: +1 781 420 2361 

Shai Biran, Ph.D. 
[email protected] 
Tel: +1 978 254 6286 

Thomas Schneckenburger, European IR & Media 
[email protected] 
Tel: +41 79 407 9952 

You May Also Be Interested In

• Quebec confirms strategic role for natural gas in long-term energy plan
• Hill Country Venture Fest Will Take the Stage at Mason's Historic Odeon Theater
• CB&I TO COMPLETE KITTIWAKE JOURNEY WITH LIFE OF FIELD CONTRACT AWARD